劫持造血系统:一个低频的JAK2V617F克隆驱动了骨髓增殖性新生体病理
Dennis M Bonal1, Alissa Oakes1, Anna Chorzalska2
1Brown University, Providence, Rhode Island, United States.
Blood
|July 29, 2025
概括
骨髓扩散性新生瘤 (MPN) 中低频率的JAK2V617F突变对骨髓层和未发生突变的细胞产生深刻影响. 这项研究揭示了MPN驱动细胞改变受体细胞形状和骨结构,挑战目前的疾病理解.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- JAK2V617F突变在不确定的潜力 (CHIP) 的克隆性血液形成中很常见,并驱动骨髓增殖性瘤 (MPN).
- 了解低频突变克隆对造血系统和骨髓层瘤的影响对于MPN研究至关重要.
研究的目的:
- 通过可追溯的小鼠模型,研究低频JAK2V617F克隆对造血细胞和骨髓层瘤的影响.
- 确定MPN驱动细胞如何影响骨髓微环境中的突变细胞和非突变细胞.
主要方法:
- 开发一种可追溯的小鼠模型,使用整个骨髓移植 (BMT) 与JAK2V617F捐赠细胞移植到接受小鼠中.
- 用RNA测序 (RNA-seq) 分析排序的骨髓细胞 (来自捐赠者和接受者) 和骨髓层.
- 微型计算机断层扫描 (micro-CT) 图像成像,以评估骨结构.
主要成果:
- 接受BMT的患者发展出一种类似于多细胞血症 (PV) 的表型,血红素和白细胞瘤水平升高.
- RNA-seq检测显示了来自供体的细胞 (红细胞/骨髓细胞的上调,淋巴细胞的下调) 和来自受体的细胞 (骨髓细胞/骨髓细胞的上调) 的转录形状变化.
- 骨髓肌瘤分析显示了骨髓介质转录的损失,微型CT证实了脊髓骨质量减少.
结论:
- 低频的JAK2V617F细胞不仅会影响造血系统,还会深刻地影响骨髓层和未变异的造血细胞.
- 这些发现挑战了关于MPN和CHIP相关疾病的病因和治疗策略的现有范式.
更多相关视频
相关概念视频
Differentiation of Common Myeloid Progenitor Cells
3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Bone Marrow Sampling and Transplants
502
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
502
Multipotency of Hematopoietic Stem Cells
3.3K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.3K
T Cell Activation and Clonal Selection
4.9K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
4.9K
Rous Sarcoma Virus (RSV) and Cancer
5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.4K


